Dopaminergic control of the globus pallidus through activation of D2 receptors and its impact on the electrical activity of subthalamic nucleus and substantia nigra reticulata neurons.
The globus pallidus (GP) receives dopaminergic afferents from the pars compacta of substantia nigra and several studies suggested that dopamine exerts its action in the GP through presynaptic D2 receptors (D2Rs). However, the impact of dopamine in GP on the pallido-subthalamic and pallido-nigral neurotransmission is not known. Here, we investigated the role of dopamine, through activation of D2Rs, in the modulation of GP neuronal activity and its impact on the electrical activity of subthalamic nucleus (STN) and substantia nigra reticulata (SNr) neurons. Extracellular recordings combined with local intracerebral microinjection of drugs were done in male Sprague-Dawley rats under urethane anesthesia. We showed that dopamine, when injected locally, increased the firing rate of the majority of neurons in the GP. This increase of the firing rate was mimicked by quinpirole, a D2R agonist, and prevented by sulpiride, a D2R antagonist. In parallel, the injection of dopamine, as well as quinpirole, in the GP reduced the firing rate of majority of STN and SNr neurons. However, neither dopamine nor quinpirole changed the tonic discharge pattern of GP, STN and SNr neurons. Our results are the first to demonstrate that dopamine through activation of D2Rs located in the GP plays an important role in the modulation of GP-STN and GP-SNr neurotransmission and consequently controls STN and SNr neuronal firing. Moreover, we provide evidence that dopamine modulate the firing rate but not the pattern of GP neurons, which in turn control the firing rate, but not the pattern of STN and SNr neurons.
Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; Université Mohamed V-Agdal, Faculté des Sciences, Equipe Rythmes Biologiques, Neurosciences et Environnement, 10000, Rabat, Morocco.
Omar
O
Mamad
Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France.
Claire
C
Delaville
Université Mohamed V-Agdal, Faculté des Sciences, Equipe Rythmes Biologiques, Neurosciences et Environnement, 10000, Rabat, Morocco.
Wail
W
Benjelloun
Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France.
Abdelhamid
A
Benazzouz
D000818:Animals; D004298:Dopamine / Q000008:administration & dosage / Q000502:physiology*; D005917:Globus Pallidus / Q000502:physiology*; D008297:Male; D008845:Microinjections; D009474:Neurons / Q000502:physiology*; D019257:Quinpirole / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D013378:Substantia Nigra / Q000166:cytology / Q000502:physiology*; D020531:Subthalamic Nucleus / Q000502:physiology*
D017448:Receptors, Dopamine D2; D019257:Quinpirole; D004298:Dopamine